MANKIND PHARMA
|
MANKIND PHARMA Last 5 Year Income Statement History
[Consolidated]
| Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 | |
|---|---|---|---|---|---|
| INCOME : | |||||
| Gross Sales | ₹14,936 Cr | ₹12,678 Cr | ₹10,677 Cr | ₹9,106 Cr | ₹8,071 Cr |
| Sales | ₹659 Cr | ₹471 Cr | ₹10,607 Cr | ₹9,048 Cr | ₹8,067 Cr |
| Job Work/ Contract Receipts | ₹28 Cr | ₹45 Cr | ₹21 Cr | ₹34 Cr | - |
| Processing Charges / Service Income | ₹14,249 Cr | ₹12,162 Cr | ₹49 Cr | ₹23 Cr | ₹3.46 Cr |
| Revenue from property development | - | - | - | - | - |
| Other Operational Income | - | - | - | - | - |
| Less: Excise Duty | - | - | - | - | - |
| Net Sales | ₹14,278 Cr | ₹12,207 Cr | ₹10,260 Cr | ₹8,749 Cr | ₹7,782 Cr |
| EXPENDITURE : | |||||
| Increase/Decrease in Stock | ₹36 Cr | ₹-183 Cr | ₹-54 Cr | ₹291 Cr | ₹-450 Cr |
| Raw Material Consumed | ₹4,016 Cr | ₹3,672 Cr | ₹3,252 Cr | ₹2,623 Cr | ₹2,871 Cr |
| Opening Raw Materials | ₹552 Cr | ₹409 Cr | ₹414 Cr | ₹399 Cr | ₹284 Cr |
| Purchases Raw Materials | ₹2,365 Cr | ₹2,160 Cr | ₹1,837 Cr | ₹1,829 Cr | ₹2,173 Cr |
| Closing Raw Materials | ₹629 Cr | ₹552 Cr | ₹409 Cr | ₹414 Cr | ₹399 Cr |
| Other Direct Purchases / Brought in cost | ₹1,728 Cr | ₹1,656 Cr | ₹1,410 Cr | ₹809 Cr | ₹814 Cr |
| Other raw material cost | - | - | - | - | - |
| Power & Fuel Cost | ₹184 Cr | ₹149 Cr | ₹125 Cr | ₹109 Cr | ₹103 Cr |
| Electricity & Power | ₹184 Cr | ₹149 Cr | ₹125 Cr | ₹109 Cr | ₹103 Cr |
| Oil, Fuel & Natural gas | - | - | - | - | - |
| Coals etc | - | - | - | - | - |
| Other power & fuel | - | - | - | - | - |
| Employee Cost | ₹3,184 Cr | ₹2,692 Cr | ₹2,261 Cr | ₹1,918 Cr | ₹1,621 Cr |
| Salaries, Wages & Bonus | ₹2,930 Cr | ₹2,488 Cr | ₹2,094 Cr | ₹1,788 Cr | ₹1,515 Cr |
| Contributions to EPF & Pension Funds | ₹137 Cr | ₹118 Cr | ₹100 Cr | ₹89 Cr | ₹74 Cr |
| Workmen and Staff Welfare Expenses | ₹51 Cr | ₹29 Cr | ₹19 Cr | ₹22 Cr | ₹15 Cr |
| Other Employees Cost | ₹66 Cr | ₹58 Cr | ₹47 Cr | ₹20 Cr | ₹17 Cr |
| Other Manufacturing Expenses | ₹337 Cr | ₹216 Cr | ₹173 Cr | ₹151 Cr | ₹160 Cr |
| Sub-contracted / Out sourced services | - | - | - | - | - |
| Processing Charges | - | - | - | - | - |
| Repairs and Maintenance | ₹72 Cr | ₹56 Cr | ₹43 Cr | ₹39 Cr | ₹37 Cr |
| Packing Material Consumed | - | - | - | - | - |
| Other Mfg Exp | ₹265 Cr | ₹161 Cr | ₹130 Cr | ₹112 Cr | ₹124 Cr |
| General and Administration Expenses | ₹1,424 Cr | ₹1,314 Cr | ₹939 Cr | ₹1,001 Cr | ₹656 Cr |
| Rent , Rates & Taxes | ₹156 Cr | ₹134 Cr | ₹89 Cr | ₹132 Cr | ₹84 Cr |
| Insurance | ₹31 Cr | ₹26 Cr | ₹18 Cr | ₹15 Cr | ₹14 Cr |
| Printing and stationery | ₹11 Cr | ₹11 Cr | ₹9.50 Cr | ₹10 Cr | ₹7.02 Cr |
| Professional and legal fees | ₹389 Cr | ₹378 Cr | ₹203 Cr | ₹169 Cr | ₹88 Cr |
| Traveling and conveyance | ₹522 Cr | ₹461 Cr | ₹378 Cr | ₹496 Cr | ₹358 Cr |
| Other Administration | ₹315 Cr | ₹304 Cr | ₹242 Cr | ₹178 Cr | ₹105 Cr |
| Selling and Distribution Expenses | ₹1,325 Cr | ₹1,165 Cr | ₹924 Cr | ₹638 Cr | ₹708 Cr |
| Advertisement & Sales Promotion | ₹798 Cr | ₹755 Cr | ₹601 Cr | ₹374 Cr | ₹452 Cr |
| Sales Commissions & Incentives | ₹283 Cr | ₹233 Cr | ₹198 Cr | ₹180 Cr | ₹174 Cr |
| Freight and Forwarding | ₹244 Cr | ₹176 Cr | ₹125 Cr | ₹84 Cr | ₹82 Cr |
| Handling and Clearing Charges | - | - | - | - | - |
| Other Selling Expenses | - | ₹0.32 Cr | ₹0.15 Cr | ₹0.28 Cr | ₹0.22 Cr |
| Miscellaneous Expenses | ₹149 Cr | ₹161 Cr | ₹125 Cr | ₹117 Cr | ₹121 Cr |
| Bad debts /advances written off | ₹10.00 Cr | ₹5.00 Cr | ₹4.62 Cr | ₹4.64 Cr | ₹4.92 Cr |
| Provision for doubtful debts | ₹10 Cr | ₹8.61 Cr | ₹7.96 Cr | ₹9.15 Cr | ₹9.65 Cr |
| Losson disposal of fixed assets(net) | ₹2.31 Cr | ₹5.37 Cr | - | - | ₹3.74 Cr |
| Losson foreign exchange fluctuations | - | - | - | - | - |
| Losson sale of non-trade current investments | - | - | - | - | - |
| Other Miscellaneous Expenses | ₹127 Cr | ₹142 Cr | ₹112 Cr | ₹103 Cr | ₹103 Cr |
| Less: Expenses Capitalised | - | - | - | - | - |
| Total Expenditure | ₹10,655 Cr | ₹9,187 Cr | ₹7,745 Cr | ₹6,848 Cr | ₹5,791 Cr |
| Operating Profit (Excl OI) | ₹3,622 Cr | ₹3,020 Cr | ₹2,515 Cr | ₹1,902 Cr | ₹1,991 Cr |
| Other Income | ₹359 Cr | ₹537 Cr | ₹280 Cr | ₹129 Cr | ₹196 Cr |
| Interest Received | ₹58 Cr | ₹68 Cr | ₹40 Cr | ₹13 Cr | ₹13 Cr |
| Dividend Received | - | - | - | ₹0.00 Cr | ₹0.00 Cr |
| Profit on sale of Fixed Assets | - | ₹2.76 Cr | ₹0.48 Cr | ₹1.67 Cr | - |
| Profits on sale of Investments | - | ₹164 Cr | - | - | - |
| Provision Written Back | ₹7.48 Cr | ₹0.81 Cr | ₹2.48 Cr | ₹4.15 Cr | ₹34 Cr |
| Foreign Exchange Gains | ₹70 Cr | ₹20 Cr | ₹8.44 Cr | ₹10 Cr | ₹8.85 Cr |
| Others | ₹223 Cr | ₹282 Cr | ₹229 Cr | ₹100 Cr | ₹140 Cr |
| Operating Profit | ₹3,981 Cr | ₹3,557 Cr | ₹2,795 Cr | ₹2,030 Cr | ₹2,187 Cr |
| Interest | ₹644 Cr | ₹432 Cr | ₹34 Cr | ₹46 Cr | ₹60 Cr |
| InterestonDebenture / Bonds | - | - | - | - | - |
| Interest on Term Loan | ₹621 Cr | ₹395 Cr | ₹19 Cr | ₹36 Cr | ₹16 Cr |
| Intereston Fixed deposits | - | - | - | - | - |
| Bank Charges etc | ₹11 Cr | ₹11 Cr | ₹6.42 Cr | ₹1.30 Cr | ₹4.02 Cr |
| Other Interest | ₹12 Cr | ₹25 Cr | ₹8.71 Cr | ₹8.42 Cr | ₹40 Cr |
| PBDT | ₹3,337 Cr | ₹3,125 Cr | ₹2,761 Cr | ₹1,985 Cr | ₹2,127 Cr |
| Depreciation | ₹886 Cr | ₹621 Cr | ₹378 Cr | ₹326 Cr | ₹167 Cr |
| Profit Before Taxation & Exceptional Items | ₹2,451 Cr | ₹2,504 Cr | ₹2,383 Cr | ₹1,659 Cr | ₹1,960 Cr |
| Exceptional Income / Expenses | ₹-130 Cr | - | - | - | - |
| Profit Before Tax | ₹2,333 Cr | ₹2,516 Cr | ₹2,398 Cr | ₹1,671 Cr | ₹1,975 Cr |
| Provision for Tax | ₹395 Cr | ₹510 Cr | ₹457 Cr | ₹362 Cr | ₹522 Cr |
| Current Income Tax | ₹539 Cr | ₹529 Cr | ₹495 Cr | ₹332 Cr | ₹451 Cr |
| Deferred Tax | ₹-161 Cr | ₹-64 Cr | ₹-31 Cr | ₹41 Cr | ₹49 Cr |
| Other taxes | ₹16 Cr | ₹45 Cr | ₹-7.22 Cr | ₹-12 Cr | ₹21 Cr |
| Profit After Tax | ₹1,938 Cr | ₹2,007 Cr | ₹1,941 Cr | ₹1,310 Cr | ₹1,453 Cr |
| Extra items | - | ₹4.53 Cr | ₹0.98 Cr | - | - |
| Minority Interest | ₹-25 Cr | ₹-20 Cr | ₹-29 Cr | ₹-28 Cr | ₹-19 Cr |
| Share of Associate | - | - | - | - | - |
| Other Consolidated Items | - | - | - | - | - |
| Consolidated Net Profit | ₹1,913 Cr | ₹1,991 Cr | ₹1,913 Cr | ₹1,282 Cr | ₹1,433 Cr |
| Adjustments to PAT | - | - | - | - | - |
| Profit Balance B/F | ₹11,907 Cr | ₹9,919 Cr | ₹8,012 Cr | ₹6,735 Cr | ₹5,304 Cr |
| Appropriations | ₹13,820 Cr | ₹11,910 Cr | ₹9,925 Cr | ₹8,017 Cr | ₹6,737 Cr |
| General Reserves | - | - | - | - | - |
| Proposed Equity Dividend | - | - | - | - | - |
| Corporate dividend tax | - | - | - | - | - |
| Other Appropriation | ₹16 Cr | ₹2.47 Cr | ₹6.27 Cr | ₹4.85 Cr | ₹1.80 Cr |
| Equity Dividend % | - | - | - | - | - |
| Earnings Per Share | ₹46.34 | ₹48.25 | ₹47.75 | ₹32.00 | ₹35.78 |
| Adjusted EPS | ₹46.34 | ₹48.25 | ₹47.75 | ₹32.00 | ₹35.78 |
Compare Income Statement of peers of MANKIND PHARMA
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| MANKIND PHARMA | ₹105,174.6 Cr | 0.6% | 7% | 4.1% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹468,458.0 Cr | 0.7% | 8.1% | 16% | Stock Analytics | |
| DIVIS LABORATORIES | ₹193,383.0 Cr | 7% | 10.2% | 3.7% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹169,829.0 Cr | 2.5% | 11.3% | 49.6% | Stock Analytics | |
| CIPLA | ₹116,164.0 Cr | -0.3% | 4.1% | -3.3% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹102,648.0 Cr | -3.2% | -3.9% | -3% | Stock Analytics | |
MANKIND PHARMA Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| MANKIND PHARMA | 0.6% |
7% |
4.1% |
| SENSEX | 0.9% |
2.2% |
-7.5% |
You may also like the below Video Courses